You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Patent: 5,730,978

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,730,978

Title:	Inhibition of lymphocyte adherence with .alpha.4.beta.1-specific antibodies
Abstract:	The present invention relates to a method for inhibiting the adhesion of one cell to another comprising interfering with the interaction between the extracellular matrix receptor and its ligand. The invention is based upon the discovery that the .alpha.4.beta.1 extracellular matrix receptor promotes adhesion of lymphocytes to endothelial cells via attachment to a defined peptide sequence. Prior to the present invention, the ligand of the .alpha.4.beta.1 receptor had not been identified, nor had the function of the .alpha.4.beta.1 receptor in lymphocyte attachment been known. By preventing the interaction between the .alpha.4.beta.1 receptor and its ligands using antibodies or defined peptide sequences, the present invention enables, for the first time, specific intervention in the migration of lymphocytes through the vascular endothelium and into tissues. The present invention, therefore, has particular clinical utility in suppression of the immune response; in various specific embodiments of the invention, the adherence of lymphocytes to endothelium may be inhibited systemically, or may, alternatively, be localized to particular tissues or circumscribed areas. Accordingly, the present invention provides for treatment of diseases involving autoimmune responses as well as other chronic or relapsing activations of the immune system, including allergy, asthma, and chronic inflammatory skin conditions.
Inventor(s):	Wayner; Elizabeth A. (St. Paul, MN)
Assignee:	Fred Hutchinson Cancer Research Center (Seattle, WA)
Application Number:	08/338,282
Patent Claims:	see list of patent claims

Details for Patent 5,730,978

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004	⤷ Try a Trial	2015-03-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 5,730,978

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Austria	253642	⤷ Try a Trial
Australia	3420693	⤷ Try a Trial
Australia	6354290	⤷ Try a Trial
Australia	654657	⤷ Try a Trial
Canada	2065292	⤷ Try a Trial
German Democratic Republic	297562	⤷ Try a Trial
Germany	122006000044	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.